CTSB and breast cancer: Most of the existing cathepsin-activatable fluorescent imaging agents are directed against cathepsin B, L, and/or S. Therefore, this immunohistochemical study investigated the expression of these cathepsins in TMAs of a large cohort of breast cancer patients.